1. Home
  2. ASO vs PBLS Comparison

ASO vs PBLS Comparison

Compare ASO & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Academy Sports and Outdoors Inc.

ASO

Academy Sports and Outdoors Inc.

HOLD

Current Price

$46.76

Market Cap

3.0B

ML Signal

HOLD

Logo Parabilis Medicines Inc. Common Stock

PBLS

Parabilis Medicines Inc. Common Stock

N/A

Current Price

$30.76

Market Cap

3.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ASO
PBLS
Founded
1938
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Recreational Games/Products/Toys
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
3.6B
IPO Year
2020
2026

Fundamental Metrics

Financial Performance
Metric
ASO
PBLS
Price
$46.76
$30.76
Analyst Decision
Buy
Analyst Count
12
0
Target Price
$58.08
N/A
AVG Volume (30 Days)
1.5M
502.7K
Earning Date
06-09-2026
N/A
Dividend Yield
1.12%
N/A
EPS Growth
N/A
N/A
EPS
0.80
N/A
Revenue
$6,053,414,000.00
N/A
Revenue This Year
$5.13
N/A
Revenue Next Year
$5.36
N/A
P/E Ratio
$58.83
N/A
Revenue Growth
2.02
N/A
52 Week Low
$41.29
$25.56
52 Week High
$62.45
$33.65

Technical Indicators

Market Signals
Indicator
ASO
PBLS
Relative Strength Index (RSI) 43.72 56.52
Support Level $43.72 $26.83
Resistance Level $59.97 $33.65
Average True Range (ATR) 1.62 2.62
MACD 0.24 0.14
Stochastic Oscillator 45.90 63.76

Price Performance

Historical Comparison
ASO
PBLS

About ASO Academy Sports and Outdoors Inc.

Academy Sports and Outdoors Inc is engaged in the full-line sporting goods and outdoor recreation retailer in the United States. The company's product categories are outdoors, apparel, sports & recreation, and footwear.

About PBLS Parabilis Medicines Inc. Common Stock

Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.

Share on Social Networks: